These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 21641409

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis.
    Hosaka K, Yang Y, Seki T, Nakamura M, Andersson P, Rouhi P, Yang X, Jensen L, Lim S, Feng N, Xue Y, Li X, Larsson O, Ohhashi T, Cao Y.
    Nat Commun; 2013; 4():2129. PubMed ID: 23831851
    [Abstract] [Full Text] [Related]

  • 4. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
    Sennino B, Kuhnert F, Tabruyn SP, Mancuso MR, Hu-Lowe DD, Kuo CJ, McDonald DM.
    Cancer Res; 2009 May 15; 69(10):4527-36. PubMed ID: 19401451
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content.
    McCarty MF, Somcio RJ, Stoeltzing O, Wey J, Fan F, Liu W, Bucana C, Ellis LM.
    J Clin Invest; 2007 Aug 15; 117(8):2114-22. PubMed ID: 17641778
    [Abstract] [Full Text] [Related]

  • 8. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
    Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM.
    J Clin Invest; 2006 Oct 15; 116(10):2610-21. PubMed ID: 17016557
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.
    Sumida T, Kitadai Y, Shinagawa K, Tanaka M, Kodama M, Ohnishi M, Ohara E, Tanaka S, Yasui W, Chayama K.
    Int J Cancer; 2011 May 01; 128(9):2050-62. PubMed ID: 21387285
    [Abstract] [Full Text] [Related]

  • 11. Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model.
    Jain RK, Lahdenranta J, Fukumura D.
    PLoS Med; 2008 Jan 29; 5(1):e24. PubMed ID: 18232729
    [Abstract] [Full Text] [Related]

  • 12. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
    Hasumi Y, Kłosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C.
    Int J Cancer; 2007 Dec 15; 121(12):2606-14. PubMed ID: 17691110
    [Abstract] [Full Text] [Related]

  • 13. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
    Kinoshita K, Nakagawa K, Hamada J, Hida Y, Tada M, Kondo S, Moriuchi T.
    Int J Oncol; 2010 Oct 15; 37(4):869-77. PubMed ID: 20811709
    [Abstract] [Full Text] [Related]

  • 14. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.
    Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L, Hajjar KA.
    Blood; 2013 Jun 27; 121(26):5192-202. PubMed ID: 23632889
    [Abstract] [Full Text] [Related]

  • 15. Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation.
    Fuxe J, Tabruyn S, Colton K, Zaid H, Adams A, Baluk P, Lashnits E, Morisada T, Le T, O'Brien S, Epstein DM, Koh GY, McDonald DM.
    Am J Pathol; 2011 Jun 27; 178(6):2897-909. PubMed ID: 21550017
    [Abstract] [Full Text] [Related]

  • 16. PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer.
    Liu J, Liao S, Huang Y, Samuel R, Shi T, Naxerova K, Huang P, Kamoun W, Jain RK, Fukumura D, Xu L.
    Clin Cancer Res; 2011 Jun 01; 17(11):3638-48. PubMed ID: 21459800
    [Abstract] [Full Text] [Related]

  • 17. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    Servidei T, Riccardi A, Sanguinetti M, Dominici C, Riccardi R.
    J Cell Physiol; 2006 Jul 01; 208(1):220-8. PubMed ID: 16575905
    [Abstract] [Full Text] [Related]

  • 18. Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas.
    Lederle W, Linde N, Heusel J, Bzyl J, Woenne EC, Zwick S, Skobe M, Kiessling F, Fusenig NE, Mueller MM.
    Am J Pathol; 2010 Feb 01; 176(2):981-94. PubMed ID: 20042679
    [Abstract] [Full Text] [Related]

  • 19. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K, Hanahan D.
    J Clin Oncol; 2005 Feb 10; 23(5):939-52. PubMed ID: 15557593
    [Abstract] [Full Text] [Related]

  • 20. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
    Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK.
    Am J Obstet Gynecol; 2008 Apr 10; 198(4):477.e1-9; discussion 477.e9-10. PubMed ID: 18395047
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.